STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing ® stent to treat acute myocardial infarction (AMI), today reports its third-quarter and 9-month revenues through 30 September 2012.
- Quarterly and 9-month revenues
|9 months||Quarterly – 3 months|
9 months 2012
9 months 2011
|Var %||Q3 2012||Q3 2011||Var %|
Revenues for the third quarter of 2012 and for the first 9 months of the year totaled €673.6 thousand and €1,823.2 thousand, respectively. These figures represent 88% growth over the first 9 months of 2011. The revenue results reflect momentum from the growing adoption of STENTYS stents by cardiologists in the 8 European countries where premarketing activities are underway.